EUNETWORKS
6.12.2022 09:46:41 CET | Business Wire | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that its Board of Directors has agreed to the appointment of Paula Cogan as its Chief Executive Officer, effective 1 January 2023. Paula currently holds the position of President, euNetworks. Paula will succeed CEO Brady Rafuse, who will become Chairman of euNetworks’ Board of Directors, with the existing Chairman Neil Hobbs remaining on the Board of Directors as a Non Executive Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221206005159/en/
Paula Cogan, euNetworks (Photo: Business Wire)
Paula is currently President, euNetworks, with responsibility for all operating aspects of the business. She joined euNetworks in November 2021, building on her 30 years of working in the telecoms industry. She has held various senior leadership positions in companies such as British Telecom, Verizon and Colt. Prior to joining euNetworks Paula was most recently Executive Vice President – Sales, Marketing and Customer Relationship Management at Colt, responsible for the commercial strategy of the business. Throughout her career Paula has been known for driving transformation in both teams and organisations, leading global sales, marketing, engineering and commercial teams as well as building successful channel strategies. With a strong track record in people management and mentoring, she is committed to promoting and driving inclusion and diversity within the telecoms Industry.
“I am excited to lead this exceptional and high-performing team of people through the next chapter of euNetworks’ growth,” said Paula Cogan. “euNetworks continues to distinguish itself in the digital infrastructure ecosystem, delivering critical internet infrastructure to customers. It’s an asset rich business, focused on developing and deepening its fibre networks, innovating and investing in new technologies to deliver highly scalable, owned and operated fibre-based and sustainable infrastructure in Europe. The vision that Brady and the team have followed and delivered creates an exciting opportunity for us all as we continue to drive the business forward. I want to thank Brady for that and also for his continued support as Chairman as we move forward in 2023.”
Brady joined euNetworks in March 2009. He has led euNetworks through its delisting on the Singapore Stock Exchange, privatisation with Columbia Capital, and sale to Stonepeak, with increased investment from IMCO. The business has become a critical bandwidth infrastructure company supporting Europe’s future bandwidth needs and a portfolio of customers who are the fastest growing consumers of bandwidth under his leadership. Brady has guided the company to become the leading data centre to data centre connectivity provider in Europe, with a unique set of connectivity options in both its metro and long haul network, including the development of Super Highways and new subsea cables. This has enabled the company to deliver exceptional growth and success, underpinned by a team with collective company values and a focus on the belief that bandwidth changes everything.
“I’m immensely proud of the team and it has been a privilege working with them as well as our investors, customers, partners and with the communities that we operate in across Europe,” said Brady Rafuse. “Paula is an exceptional leader. Her achievements in her career have been underpinned by her ability to foster strong relationships with customers and partners whilst remaining focused on leading organisations and people. Paula joined the euNetworks team a year ago and since then we have been working closely to ensure a smooth transition as we move forward with our plans and continue to grow the business. With Paula’s focus over the last year on all operating aspects of the business and her customer-centric approach, she has already made a great contribution to our performance in 2022 and I am excited for the company’s future with Paula as CEO. Thank you to Neil for his support, contribution and guidance since joining the euNetworks Board of Directors in January 2014. His extensive and global board and management experience has been hugely valuable to us all during his time as Chairman on our Board.”
“We know Paula is a fantastic leader and, like Brady, has a clear vision to guide euNetworks as we progress with growth plans for the business,” said Cyrus Gentry, Managing Director and Head of Communications, Europe at Stonepeak. “euNetworks is the fastest growing fibre business in Europe. It has a highly differentiated network platform that underpins the digital infrastructure ecosystem and there remains no shortage of compelling capital opportunities in Europe for euNetworks to further build on the unique position it has in the region. We extend our thanks to Brady for everything he has delivered as CEO, and we look forward to the value he will continue to deliver as Chairman.”
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 490 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
About Stonepeak
Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $51.7 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, and to have a positive impact on the communities in which it operates. Stonepeak sponsors investment vehicles focused on private equity and credit. The firm provides capital, operational support, and committed partnership to sustainably grow investments in its target sectors, which include communications, energy transition, transport and logistics, and social infrastructure. Stonepeak is headquartered in New York with offices in Austin, Hong Kong, Houston, London and Sydney. For more information, please visit www.stonepeak.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005159/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
